USFDA nod to Novartis Tafinlar plus Mekinist for solid tumors with gene mutation Ruchika Sharma23 Jun 2022 2:47 PM ISTBRAF V600E is the most common type of BRAF mutation, accounting for up to 90% of BRAF-mutant cancers.
Setback to Novartis: US Court declares multiple sclerosis drug Gilenya patent invalid Ruchika Sharma22 Jun 2022 12:30 PM ISTNovartis also said it believes HEC and others cannot launch generic versions of Gilenya during the ongoing appeal process.
Herve Berdou appointed as Piramal Pharma Solutions new Chief Operating Officer Ruchika Sharma22 Jun 2022 11:41 AM ISTMumbai: Piramal Pharma Limited's Pharma Solutions business has announced the appointment of Herve Berdou as Chief Operating Officer, Piramal Pharma...
Novartis division Sandoz application for proposed biosimilar Hyrimoz's high concentration formulation accepted by EMA Ruchika Sharma19 Jun 2022 11:30 AM ISTUpon approval, the Hyrimoz (100 mg/mL) citrate-free HCF would offer reduced injection volume and potentially decrease the number of injections...
Novartis Tafinlar, Mekinist combination shows promise in childhood brain cancer Ruchika Sharma7 Jun 2022 3:22 PM ISTThe trial only included those who were found to have a mutation known as BRAF V600, a genetic contributor in about 15% to 20% of pediatric LGG cases.
Novartis Kymriah gets USFDA nod for relapsed or refractory follicular lymphoma Ruchika Sharma30 May 2022 12:19 PM IST"Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings," claims the...
Minister says Hyderabad emerges as second largest base for Novartis Ruchika Sharma25 May 2022 1:10 PM ISTThe growth of Novartis in Hyderabad serves as the testimony to Hyderabad’s growing R&D prowess and extraordinary talent pool.
Novartis Cosentyx gets positive CHMP opinion for expanded use in childhood arthritic conditions Ruchika Sharma23 May 2022 10:00 AM ISTBasel: Novartis has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...
Novartis gets European Commission nod for Jakavi to treat acute, chronic graft-versus-host disease Ruchika Sharma8 May 2022 10:15 AM ISTGvHD occurs when donor cells see the recipient's healthy cells as foreign and attack them.
Novartis suspends two cancer therapies over quality concerns Ruchika Sharma6 May 2022 12:19 PM ISTZurich: Novartis said on Thursday it had temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy...
Novartis to cut thousands of jobs in global revamp: Sources Ruchika Sharma13 April 2022 9:00 AM ISTZurich: Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced...
Novartis gets USFDA accelerated approval for PIK3CA-Related Overgrowth Spectrum treatment Vijoice Ruchika Sharma7 April 2022 11:58 AM ISTBasel: Novartis has recently announced that the U.S. Food and Drug Administration (USFDA) has granted accelerated approval to Vijoice (alpelisib) for...
